Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
INK Cell Therapy(Guangzhou Ruixin Biotechnology) in Acute Myeloid Leukemia: NCT06702098 Clinical Landscape Report 2026
16 October 2026
NCT06702098 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BSB-1001 in Acute Lymphoblastic Leukemia: NCT06704152 Clinical Landscape Report 2026
16 October 2026
NCT06704152 clinical landscape for Acute Lymphoblastic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TQB2029 in Multiple Myeloma: NCT06700395 Clinical Landscape Report 2026
16 October 2026
NCT06700395 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ABP-692 in Multiple Sclerosis, Relapsing-Remitting: NCT06700343 Clinical Landscape Report 2026
16 October 2026
NCT06700343 clinical landscape for Multiple Sclerosis, Relapsing-Remitting: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Alvimopan Dihydrate in Bladder Cancer: NCT06703476 Clinical Landscape Report 2026
16 October 2026
NCT06703476 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitomycin in Non-Muscle Invasive Bladder Neoplasms: NCT06704191 Clinical Landscape Report 2026
16 October 2026
NCT06704191 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
CBG002 in Multiple Myeloma: NCT06705725 Clinical Landscape Report 2026
16 October 2026
NCT06705725 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Scleroderma, Diffuse: NCT06708845 Clinical Landscape Report 2026
16 October 2026
NCT06708845 clinical landscape for Scleroderma, Diffuse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19 CAR-T CELLS(Gaia Science) in Systemic Lupus Erythematosus: NCT06710717 Clinical Landscape Report 2026
16 October 2026
NCT06710717 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivosidenib in IDH1 Mutation Acute Myeloid Leukemia: NCT06707493 Clinical Landscape Report 2026
16 October 2026
NCT06707493 clinical landscape for IDH1 Mutation Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Ianalumab in Lupus Nephritis: NCT06711887 Clinical Landscape Report 2026
16 October 2026
NCT06711887 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AMDINOCILLIN PIVOXIL in Postoperative infection: NCT06709196 Clinical Landscape Report 2026
16 October 2026
NCT06709196 clinical landscape for Postoperative infection: endpoints, sponsor, phase, geography, readouts, asset context and development white space.